EVGN - Evogene Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.03
-0.07 (-2.26%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.10
Open3.04
Bid0.00 x 1100
Ask0.00 x 1100
Day's Range2.94 - 3.10
52 Week Range2.66 - 5.75
Volume18,011
Avg. Volume10,731
Market Cap77.446M
Beta0.34
PE Ratio (TTM)N/A
EPS (TTM)-0.83
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • ACCESSWIRE19 days ago

    Blog Exposure - Evogene Signs Collaboration Agreement with BASF for Development of Novel Insecticides

    LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want access to our free research report on Evogene Ltd (NASDAQ: EVGN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EVGN as the Company's latest news hit the wire. On May 29, 2018, the Company, which is a leading biotechnology organization developing novel products for life science markets, and BASF, which is one of the world's leading chemical Companies, declared on May 29, 2018, that they have signed a new collaboration agreement for the development of novel insecticides based on new binding areas (Site-of-Action or ‘SoA') on key insecticidal target proteins. Active-Investors.com is currently working on the research report for Oncobiologics, Inc. (NASDAQ: ONS), which also belongs to the Healthcare sector as the Company Evogene.

  • Associated Press21 days ago

    Evogene: 1Q Earnings Snapshot

    On a per-share basis, the Rehovot, Israel-based company said it had a loss of 21 cents. The agricultural company posted revenue of $366,000 in the period. The company's shares closed at $3.10. A year ago, ...

  • GlobeNewswire21 days ago

    Evogene Reports First Quarter 2018 Financial Results

    REHOVOT, Israel, May 29, 2018-- Evogene Ltd., a leading biotechnology company developing novel products for life science markets, announced today its financial results for the first quarter ending March ...

  • GlobeNewswire21 days ago

    BASF and Evogene announce multiyear collaboration for the development of novel insecticides

    BASF, one of the world’s leading chemical companies, and Evogene Ltd. (EVGN) (EVGN.TA), a leading biotechnology company developing novel products for life science markets, announced today a new collaboration focusing on the development of novel insecticides based on new binding areas (Site-of-Action or ‘SoA’) on key insecticidal target proteins. The parties also announced that the collaboration achieved its first project milestone, with the joint nomination of a set of novel SoAs, discovered by Evogene that will advance to the discovery phase of relevant bioactive compounds. In the initial phase of the collaboration, using their strong background in computational methods, Evogene has developed a smart process to identify potential novel compounds that act on new proteins and binding sites.

  • GlobeNewswirelast month

    Biomica Announces Participation in the Microbiome Invest Conference in London May 23, 2018

    REHOVOT, Israel, May 14, 2018-- Biomica, a subsidiary of Evogene Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene's Computational Predictive ...

  • GlobeNewswirelast month

    Evogene Financial Results for the First Quarter of 2018 Earnings Announcement Schedule

    REHOVOT, Israel, May 10, 2018-- Evogene Ltd., a leading biotechnology company developing novel products for life science markets, announced today that it will release its financial results for the first ...

  • GlobeNewswirelast month

    Evogene and Marrone Bio Innovations Announce Phase Advancement in their Insect Control Collaboration

    Evogene Ltd. (EVGN) (EVGN.TA), a leading biotechnology company developing novel products for life science markets, and Marrone Bio Innovations Inc. (MBI), (MBII), a leading global provider of bio-based pest management and plant health products, announced today advancement of genes into Phase I in their insect control collaboration following positive results in model plants. Novel genes isolated from MBI’s microbial assets were discovered as part of Evogene’s Ag-Seeds division collaboration with MBI and showed insecticidal activity against numerous insects from the Lepidoptera and Hemiptera orders in model plants. The Evogene Ag-Seeds division and MBI insect control collaboration was initiated in July 2014 with the mission of bringing to market novel microbe-based insect control solutions viz.

  • GlobeNewswire2 months ago

    Biomica, Evogene’s Newly Established Subsidiary, Announces Therapeutic Areas of Focus

    Biomica, a subsidiary of Evogene Ltd. (EVGN) (EVGN.TA), an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene's Computational Predictive Biology (CPB) platform, announced today its focus on the development of therapies for antibiotic resistant bacteria, Immuno-Oncology and GI related disorders. The human gut microbiome is the collection of trillions of micro-organisms that exist in the digestive tract. The search for microbiome therapies and treatments is a rapidly growing focus for bio-therapeutics research and development, with the potential to reach $9.9Bn annual sales by 20242.

  • GlobeNewswire3 months ago

    Evogene Files Annual Report for the Year Ended December 31, 2017

    REHOVOT, Israel, April 01, 2018-- Evogene Ltd., a leading biotechnology company developing novel products for life science markets through the use of a unique Computational Predictive Biology platform, ...

  • Associated Press4 months ago

    Evogene reports 4Q loss

    The Rehovot, Israel-based company said it had a loss of 24 cents per share. The agricultural company posted revenue of $734,000 in the period. For the year, the company reported that its loss widened to ...

  • ACCESSWIRE4 months ago

    Evogene Ltd to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Evogene Ltd (NASDAQ: EVGN ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 28, 2018 at 9:00 AM Eastern Time. ...

  • Associated Press7 months ago

    Evogene reports 3Q loss

    The Rehovot, Israel-based company said it had a loss of 20 cents per share. The agricultural company posted revenue of $748,000 in the period. The company's shares closed at $3.79. A year ago, they were ...

  • Capital Cube8 months ago

    ETFs with exposure to Evogene Ltd. : October 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Evogene Ltd. Here are 5 ETFs with the largest exposure to EVGN-US. Comparing the performance and risk of Evogene Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Evogene Ltd. :EVGN-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
    Capital Cube8 months ago

    Evogene Ltd. :EVGN-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017

    Categories: Yahoo FinanceGet free summary analysis Evogene Ltd. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 1.18 million, Net Earnings of USD -4.74 million. Gross margins widened from 12.89% to 13.58% compared to the same period last year, operating (EBITDA) margins now -392.28% from -254.20%. Change in operating cash ... Read more (Read more...)